COVID-19 Does Not Influence the Time to Relapse Following Dupilumab Discontinuation in Patients With Moderate-to-Severe Atopic Dermatitis
Get full access to this article
View all available purchase options and get full access to this article.
REFERENCES
1. Merola JF, Sidbury R, Wollenberg A, et al. Dupilumab prevents flares in adults with moderate to severe atopic dermatitis in a 52-week randomized controlled phase 3 trial. J Am Acad Dermatol. 2021;84:495–497.
2. Blauvelt A, Guttman-Yassky E, Paller AS, et al. Long-term efficacy and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis: results through week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE). Am J Clin Dermatol. 2022;23:365–383.
3. Potestio L, Napolitano M, Bennardo L, et al. Atopic dermatitis exacerbation after Covid-19 vaccination in Dupilumab-treated patients. J Eur Acad Dermatol Venereol. 2022;36:e409–411.
4. Pourani MR, Ganji R, Dashti T, et al. Impact of COVID-19 pandemic on patients with atopic dermatitis. Actas Dermosifiliogr. 2022;113:286–293.
5. Tang TS, Bieber T, Williams HC. Are the concepts of induction of remission and treatment of subclinical inflammation in atopic dermatitis clinically useful? J Allergy Clin Immunol. 2014;133:1615–1625 e1611.
6. Russo F, Cioppa V, Cartocci A, et al. Dupilumab and atopic dermatitis flares: an observational study to identify common clinical features in patients who have exacerbations despite biological therapy. Dermatitis. In Press; 2023.
Information & Authors
Information
Published In
Copyright
© 2023 American Contact Dermatitis Society. All Rights Reserved.
History
Published online: 27 September 2024
Published in print: September/October 2024
Published ahead of print: 29 December 2023
Topics
Authors
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Get Access
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.